Showing results (211-220 of 226) with videos related to

Sort By:
Pageof 23
Molecular Cancer Therapeutics|December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Cell|April 21, 2018
GPR68 Senses Flow and Is Essential for Vascular PhysiologyJie Xu, Jayanti Mathur, Emilie Vessières, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica|April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axisAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Oncotarget|April 2, 2016
MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanibSandra Lassalle, Joséphine Zangari, Alexandra Popa, et al.
Journal of Medicinal Chemistry|October 30, 2023
4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1<i>H</i>-pyrrol-1-yl)benzenesulfonamide, a Novel Carbonic Anhydrase and Wnt/β-Catenin Signaling Pathway Dual-Targeting Inhibitor with Potent Activity against Multidrug Resistant Cancer CellsDomiziana Masci, Michela Puxeddu, Laura Di Magno, et al.
Haematologica|November 2, 2020
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma modelsEugenio Gaudio, Chiara Tarantelli, Filippo Spriano, et al.
Nature Immunology|December 22, 2022
Staphylococcal phosphatidylglycerol antigens activate human T cells via CD1aGwennaëlle C Monnot, Marcin Wegrecki, Tan-Yun Cheng, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory DiseasesXiaohui He, Sara Da Ros, John Nelson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination TherapyChiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Pageof 23